De Cannabis sativa , Nederlandse naam ‘hennep’, is een plant die in grote delen van de wereld in de vrije natuur voorkomt. Zowel in de tropen en subtropen als in de gematigde klimaatzones gedijt hij uitstekend. Sinds mensenheugenis wordt de plant voor verschillende doeleinden gekweekt: als grondstof voor textiel, als medicijn en natuurlijk wegens de psychoactieve eigenschappen, al dan niet toegepast in religieuze ceremonies. Het is één van de oudste cultuurplanten.
Preview
Unable to display preview. Download preview PDF.
Referenties
Barbers RG. et al. Differential examination of bronchoalveolar lavage cells in tobacco cigarette and marijuana smokers. Am Rev Respir Dis 1987; 135(6): 1271–1275.
Bloom JW. et al. Respiratory effects of non-tobacco cigarettes. Br Med J (Clin Res Ed) 1987; 295(6612): 1516–1518.
Brink W van den. Hoe schadelijk zijn softdrugs? Justitie verken 2006; 32: 72–88.
Brink W van den. Verslaving: een chronisch recidiverende hersenziekte. Justitie verken 2006; 32: 59–75.
Carai MA, Colombo G, Gessa GL. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 2005; 77(19): 2339–2350.
Christensen R. et al. Efficacy and safety of the weight-loss drug rimonabant: a metaanalysis of randomised trials. Lancet 2007; 370(9600): 1706–1713.
Coates RA. et al. Cofactors of progression to acquired immunodeficiency syndrome in a cohort of male sexual contacts of men with human immunodeficiency virus disease. Am J Epidemiol 1990; 132(4): 717–722.
Decorte T, Muys M, Slock S. Cannabis in Vlaanderen. Patronen van cannabisgebruik bij ervaren gebruikers. Leuven/Leusden: Acco; 2003.
Devane WA. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258(5090): 1946–1949.
Di Marzo V, Petrocellis LD. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006; 57: 553–574.
El-Gohary M, Eid MA. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum Exp Toxicol 2004; 23(3): 149–156.
Fergusson DM. et al. Cannabis and psychosis. Bmj 2006; 332(7534): 172–175.
Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 2006; 101(4): 556–569.
Fergusson DM, Horwood LJ, Beautrais AL. Cannabis and educational achievement. Addiction 2003; 98(12): 1681–1692.
Fried PA. Prenatal exposure to tobacco and marijuana: effects during pregnancy, infancy, and early childhood. Clin Obstet Gynecol 1993; 36(2): 319–317.
Gieringer D. Marijuana research: Waterpipe study. MAPS (Multidisciplinary Association for Psychedelic Studies) Bulletin 1996; 6: 59–66.
Gong H. et al. Tracheobronchial changes in habitual, heavy smokers of marijuana with and without tobacco. Am Rev Respir Dis 1987; 136(1): 142–149.
Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 2005; 6(1): 35–42.
Harrison GP. et al. Cognitive measures in long-term cannabis users. J Clin Pharmacol 2002; 42(11 Suppl): 41S–47S.
Hashibe M. et al. Epidemiologic review of marijuana use and cancer risk. Alcohol 2005; 35(3): 265–265.
Hashibe M. et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2006; 15(10): 1829–1824.
Hazekamp A. et al. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006; 95(6): 1308–1317.
Heishman SJ, Stitzer ML, Yingling JE. Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav 1989; 34(1): 173–179.
Hollister L. Marijuana and immunity. J Psychoactive Drugs 1992; 24: 159–164.
Iversen L. The science of marijuana. Oxford: University Press; 2000.
Kaslow R. et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals: a report from the Multicentre AIDS Cohort Study, JAMA 1989; 261: 3424–3429.
Korf D. De normalisering van cannabisgebruik. Justitie verken 2006; 32: 61–71.
Korf DJ. Dutch coffee shops and trends in cannabis use. Addict Behav 2002; 27(6): 851–866.
Korf DJ. et al. Sterke wiet. Een onderzoek naar blowgedrag, schadelijkheid en afhankelijkheid van cannabis. Amsterdam: Rozenberg Publishers; 2004.
Kraft U. Natural High. Scien Am Mind 2006; 17: 61–65.
Laar M van. et al. Nationale Drug Monitor. Jaarbericht 2006. Utrecht: Trimbos Instituut; 2007.
Lyketsos CG. et al. Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiol 1999; 149(9): 794–800.
Lynskey MT. et al. Stimulant use and symptoms of abuse/dependence: epidemiology and associations with cannabis use - a twin study. Drug Alcohol Depend 2007; 86(2-3): 147–153.
Moore TH. et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370(9584): 319–328.
Morral AR, McCaffrey DF, Paddock SM. Reassessing the marijuana gateway effect. Addiction 2002; 97(12): 1493–1504.
Niesink R. et al. THC-concentraties in wiet, nederwiet en hasj in Nederlandse coffeeshops (2005–2006). Utrecht: Trimbos Instituut, DIMS; 2006.
Pacifici R. et al. Modulation of the immune system in cannabis users. Jama 2003; 289(15): 1929–1931.
Pope HG. et al. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69(3): 303–310.
Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66(2): 234–246.
Scharen H van. De Cannabis connectie. Antwerpen: Uitgeverij Hadewijch; 1997.
Segev L, Paz A, Potasman I. Drug abuse in travelers to southeast Asia: an on-site study. J Travel Med 2005; 12(4): 205–209.
Solowij N. et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. Jama 2002; 287(9): 1123–1131.
Stella N. Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388(6644): 773–778.
Sydow K von. et al. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend 2002; 68(1): 49–64.
Tashkin D. et al. Effects of habitual use of marijuana and/or cocaine on the lung. In: Research findings on smoking of abused substances. NIDA Research Monograph 1997; 99: 63–87.
Tashkin, DP. et al. Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. Am Rev Respir Dis 1987; 135(1): 209–216.
Tashkin DP. et al. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 2002; 42(11 Suppl): 718–781.
Taylor D. et al. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. Addiction 2002; 97: 1055–1061.
Zuckerman B. et al. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 1989; 320(12): 762–768.
Websites
www.eelda.org. Evidence-based Electronic Library for Drugs and Addiction.
Editor information
Copyright information
© 2008 Bohn Stafleu van Loghum
About this chapter
Cite this chapter
Vervaeke, H. (2008). Tripmiddelen: cannabis. In: Kerssemakers, R., Van Meerten, R., Noorlander, E., Vervaeke, H. (eds) Drugs en alcohol; Gebruik, misbruik en verslaving. Bohn Stafleu van Loghum, Houten. https://doi.org/10.1007/978-90-313-6554-8_12
Download citation
DOI: https://doi.org/10.1007/978-90-313-6554-8_12
Publisher Name: Bohn Stafleu van Loghum, Houten
Print ISBN: 978-90-313-5059-9
Online ISBN: 978-90-313-6554-8
eBook Packages: Dutch language eBook collection